Top Medical News
Head, neck involvement tied to poor prognosis in patients with mycosis fungoides
9 hours ago
Head and neck involvement of mycosis fungoides is a predictor of a poor prognosis, according to a recent study.
Surgery plus radiotherapy no better than surgery alone in cutaneous squamous cell carcinoma
Poor outcomes are not significantly different in between patients with high-risk cutaneous squamous cell carcinomas treated with margin-negative resection only and those who underwent surgery with adjuvant radiotherapy, reveals a study.
Steroid plus anti-TNF-α proven effective in SJS/TEN
The addition of antitumour necrosis factor-alpha (anti-TNF-α) to steroid treatment may help improve outcomes for patients with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), suggest the results of a recent study.
Lenabasum effective, well tolerated in refractory dermatomyositis
14 May 2022
In the treatment of patients with refractory cutaneous dermatomyositis, the cannabinoid receptor type 2 agonist lenabasum yields good outcomes in terms of efficacy and safety, as indicated by improvements in disease activity and no increased risk of serious or severe adverse events, according to the results of a phase II study.
Lirentelimab shows promise in treatment-resistant chronic urticaria
14 May 2022
In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.
Depression, anxiety aggravated in vitiligo patients
14 May 2022
Vitiligo patients suffer from greater levels of depression and anxiety, both of which appear to be associated with serum levels of corticotropin releasing hormone, reveals a recent study.
Early breast cancer: AIs reduce recurrence vs tamoxifen in premenopausal women
13 May 2022
A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.
Special Reports
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Cochrane review confirms Atopiclair efficacy in eczema
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Conference Reports
Baricitinib may improve hair regrowth in alopecia areata
Roshini Claire Anthony, 02 May 2022

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

Dupilumab stops the itch, clears skin lesions in phase III trial
Elvira Manzano, 29 Apr 2022
The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.
Roflumilast cream reduces psoriasis severity
Elaine Soliven, 27 Apr 2022
Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.
Cutaneous reactions after 1st COVID-19 vaccine dose no reason to forgo 2nd dose
Elvira Manzano, 27 Apr 2022
Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.
Ruxolitinib cream improves repigmentation in patients with vitiligo
Elaine Soliven, 09 Nov 2021
The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.
Ritlecitinib prevents hair loss in patchy baldness
Pearl Toh, 22 Oct 2021
The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.
Elaine Soliven, 22 Oct 2021
Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.
Product Highlights
CME Modules